Recombinant Human Ly6K Fc Chimera Protein, CF

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion by human T cells. The ED50 for this effect is 0.75-7.5 μg/mL.

2 μg/lane of Recombinant Human Ly6K Fc Chimera Protein (Catalog # 10648-L6) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 41-61 kDa and 82-122 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Ly6K Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 0.75-7.5 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Ly6K protein
  

  Human Ly6K (Asp18-Gly138) Accession # Q17RY6.2	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q17RY6.2
• N-terminal Sequence: Asp18
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 41 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 41-61 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Ly6K Fc Chimera Protein, CF

• cancer/testis antigen 97
• CO16
• CT97
• FLJ35226
• HSJ001348
• Ly6K
• ly-6K
• lymphocyte antigen 6 complex, locus K
• lymphocyte antigen 6K

Background

Lymphocyte antigen 6 complex, locus K (Ly6K) is a member of the LY6/urokinase-type plasminogen activator receptors (uPARS) family which participate in a wide range of functions from cell proliferation and migration to cytokine production (1). In humans, there are over 30 Ly6/uPARS members, characterized by a conserved, three-fingered disulfide linked LU domain that creates structural motif and a glycosylphosphatidylinositol (GPI)-anchoring site (2, 3). Members of the family are categorized as transmembrane or secretory depending on the presence of a GPI-anchored signal sequence. Mature LY6K contains an extracellular domain (ECD) with a single LU domain and a GPI-anchoring site. Within the ECD, human Ly6K shares 39% and 36% amino acid sequence identity with mouse and rat Ly6K, respectively. Human Ly6K is strongly expressed in testis and is crucial for the production of fertile spermatozoa (4). Additionally, Ly6K has been shown to be upregulated in a number of types of cancer and promotes tumor cell proliferation and metastasis and is a potential cancer therapy target (5). Furthermore, Ly6K promotes glioblastoma tumorigenicity via caveolin-1–mediated ERK1/2 signaling (6). The over-expression of Ly6K suppresses T cell development in the in vivo mouse model (7).

1. Loughner, C.L. et al. (2016) Hum Genomics. 10:10.
2. Upadhyay, G. (2019) Front. Immunol. 10:819.
3. Song, D. et al. (2018) Oncol. Lett. 17:379.
4. Endo S. et al. (2016) Sci. Rep. 6:23616.
5. Benti, S. et al. (2020) Cancers 12:509.
6. Sastry, N.G. et al. (2020) Neuro-Oncology. 22:1315.
7. Son D. et al. (2019) Oncol. Lett. 17:379.

Bioinformatics

• Uniprot:
  • Q17RY6.2()